News
-
-
-
PRESS RELEASE
GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
GENFIT to join CAC Mid 60 and SBF 120 indices on Euronext Paris after annual review, enhancing visibility and market profile. CEO Pascal Prigent confirms company's commitment to innovative therapies and long-term value creation -
-
-
REGULATED PRESS RELEASE
BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Biophytis completes €5.3 million capital increase to fund Phase 2 trial in obesity, balancing US and European investors. Proceeds target fat loss and muscle preservation with BIO101 -
-
-
-